News

Select Year
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
May 6, 2022 4:05 PM
EDT
2022
Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022
Download
May 2, 2022 4:05 PM
EDT
2022
Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022
Download
April 19, 2022 7:10 AM
EDT
2022
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
Download
April 4, 2022 4:11 PM
EDT
2022
Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings
Download
March 3, 2022 4:31 PM
EST
2022
Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences
Download
February 28, 2022 6:00 AM
EST
2022
Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates
Download
February 9, 2022 4:17 PM
EST
2022
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2022
Download
February 3, 2022 7:05 AM
EST
2022
Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference
Download
January 4, 2022 4:17 PM
EST
2022
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences
Download
December 9, 2021 6:15 AM
EST
2021
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)
Download
November 10, 2021 4:05 PM
EST
2021
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
Download
November 3, 2021 6:00 AM
EDT
2021
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
Download
November 1, 2021 10:12 AM
EDT
2021
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis
Download
October 27, 2021 7:07 AM
EDT
2021
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021
Download
October 26, 2021 4:10 PM
EDT
2021
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021
Download
September 17, 2021 6:05 AM
EDT
2021
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases
Download
September 15, 2021 1:11 PM
EDT
2021
Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences
Download
September 10, 2021 1:30 PM
EDT
2021
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
Download
August 9, 2021 7:55 AM
EDT
2021
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference
Download
August 5, 2021 4:05 PM
EDT
2021
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights
Download
July 26, 2021 6:05 AM
EDT
2021
Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021
Download
July 16, 2021 5:30 PM
EDT
2021
Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange
Download
June 30, 2021 7:05 AM
EDT
2021
Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs
Download
June 25, 2021 5:14 AM
EDT
2021
Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)
Download
June 14, 2021 6:05 AM
EDT
2021
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
Download
No Results Found
Please try different keywords or filters.

Email Alerts

By providing your email address above, you are providing consent to Aurinia Pharmaceuticals Inc. to send you the requested Investor Email Alert updates. For information on how we protect your information, please refer to our Privacy Policy.
Thank you! Your message has been sent!
Oops! There was an error with your submission.